Figure 2
Engraftment capacity during different cardiac differentiation stages.
(a) Engraftment ratio in the first 2 months after injection into healthy heart. iPSCs and day4 mesodermal cells, n = 5 each; day8, 20 and 30 iPSC-CMs, n = 7 each. Values are mean ± SE. (b) Engraftment ratio of purified CMs (day8, 20 and 30, n = 7 each) at 1, 4 and 8 weeks after the initial injection. Values are mean ± SE. *p < 0.05 by one-way ANOVA followed by Tukey’s posthoc test. (c) Engraftment ratio in the first 2 months after injection into infarcted heart. iPSCs, day4 mesodermal cells and day8, 20 and 30 iPSC-CMs, n = 4 each. Values are mean ± SE. (d) Immunostaining of engrafted CMs in infarcted heart at each differentiation stage for cTNT (red), anti-luciferase (luc) (yellow) and Hoechst (blue). Scale bars: 300 μm. (e) Immunostaining of engrafted CMs in infarcted hearts at high magnification: red, cTNT; yellow, anti-luc; blue, Hoechst. Scale bars: 20 μm.
